{"id":5569,"date":"2025-10-16T13:59:36","date_gmt":"2025-10-16T19:59:36","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=5569"},"modified":"2025-10-17T09:09:20","modified_gmt":"2025-10-17T15:09:20","slug":"the-antifungal-landscape-1","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2025\/10\/16\/5569\/the-antifungal-landscape-1\/","title":{"rendered":"The Antifungal Landscape – 1"},"content":{"rendered":"
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

Some newer azoles are still in development, but most only target candidiasis.  Many years ago we saw development of nikkomycin (Nik Z), a drug mainly for coccidioidomycosis (Valley Fever).  It has no appreciable activity against candida or aspergillus.  Then there is ibrexafungerp, a promising new agent against C. albicans and C. auris but again without activity against aspergillus.<\/p>\n\n\n\n

Aspergillus AND Candida coverage are critically important in immunocompromised patients. Aspergillus drugs in particular are needed nowadays to replace amphotericin B (AMB).<\/p>\n\n\n\n

Here is a side-by-side tabulation of key features of newer antifungals. Below are some in-depth references. Highly anticipated are olorofim, which was discussed recently, and fosmanogepix, that has been moving forward rapidly and is also now in Phase 3.<\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n\n

Fosmanogepix is the new kid on the block.  As a Gwt1 enzyme inhibitor, it introduces a novel MoA and has great activity against Candida and Aspergillus. It holds much promise and its path through clinical development will be the topic of an upcoming blog.<\/p>\n\n\n\n

Stay tuned and come back for more!<\/p>\n\n\n\n

ABBREVIATIONS
<\/strong>LD            loading dose
RVVC      recurrent vulvovaginal candidiasis<\/p>\n\n\n\n

REFERENCES
<\/strong>Hoenigl M. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.  Clin Microbiol Rev. 37 (2): 1, 2024
<\/span>Johnson M.  Current Antifungals and the Developing Pipeline.  Infect Dis Clin N Am 39 (2025) e1
Kriegl L. New treatment options for critically important WHO fungal priority pathogens.  Clinical Microbiology and Infection 31 (2025) 922<\/p>\n\n\n\n

NOTE:  Some name changes
<\/strong>Nakaseomyces glabrata                    formerly Candida glabrata
<\/span>Candidozyma auris                            formerly Candida auris<\/p>\n","protected":false},"excerpt":{"rendered":"

Some newer azoles are still in development, but most only target candidiasis.  Many years ago we saw development of nikkomycin (Nik Z), a drug mainly for coccidioidomycosis (Valley Fever).  It has no appreciable activity against candida or aspergillus.  Then there is ibrexafungerp, a promising new agent against C. albicans and Continue reading The Antifungal Landscape – 1<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":5574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[227,3],"tags":[403,2495,650,595,2497,2499,651,642,649,1340,2431,2500,1583,2464,599,251,2461,641,2462,1525,2496,2498,485,604],"class_list":["post-5569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","tag-antibiotic-blog","tag-antifungal-pipeline","tag-aspergillus","tag-basilea","tag-brexafemme","tag-c-auris","tag-candida","tag-coccidioidomycosis","tag-cryptococcosis","tag-f2g","tag-fosmanogepix","tag-gwt1-inhibitor","tag-harald-reinhart","tag-ibrexafungerp","tag-melinta","tag-moa","tag-nik-z","tag-nikkomycin","tag-olorofim","tag-pneumocystis","tag-rezafungin","tag-rezzayo","tag-scynexis","tag-valley-fever-solutions"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/HR_SLIDER-The-Antifungal-Landscape-1.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1rP","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1079,"url":"https:\/\/allphasepharma.com\/dir\/2014\/10\/16\/1079\/nikkomycins-are-finally-getting-some-respect\/","url_meta":{"origin":5569,"position":0},"title":"Nikkomycins Are Finally Getting Some Respect","author":"Harald","date":"October 16, 2014","format":false,"excerpt":"Besides azoles, candins and the polyene class of antifungals there is not much to select from when it comes to systemic fungal infections.\u00a0 Until the recent arrival of voriconazole and posaconazole, infections caused by molds always required amphotericin B to control.\u00a0 Only for Candida several good treatments exist on the\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/cocci-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/cocci-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/cocci-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":5500,"url":"https:\/\/allphasepharma.com\/dir\/2025\/09\/29\/5500\/draft-fda-guidance-for-coccidioidomycosis\/","url_meta":{"origin":5569,"position":1},"title":"Draft FDA Guidance for COCCIDIOIDOMYCOSIS","author":"Harald","date":"September 29, 2025","format":false,"excerpt":"David Larwood, CEO of VFS, summed it up at the Cocci FDA workshop in 2020: \u201cWhen the market opportunity is limited, finding investment becomes the key issue\u201d.\u00a0 He mentioned other problems as well: \u201cVery low patient numbers for disseminated disease, prolonged therapy, NI trial design, definition of clinical outcome\u201d.[1] Clearly,\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Haboob.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Haboob.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Haboob.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":344,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/19\/344\/the-amazing-sulfonamides\/","url_meta":{"origin":5569,"position":2},"title":"The Amazing Sulfonamides","author":"Harald","date":"June 19, 2014","format":false,"excerpt":"Sulfonamides really cover more infectious territory than most other antibiotics. Besides the more common bacterial species, they are\u00a0active\u00a0against many 'special' pathogens, like S. maltophilia,\u00a0P. jiroveci, Listeria, Nocardia,, C. burneti (Q-fever), and T. whipplei (Whipple's disease). Not to forget their\u00a0use in malaria, toxoplasmosis, \u00a0melioidosis, cyclospora, and atypical mycobacterial infections. Then there\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":5576,"url":"https:\/\/allphasepharma.com\/dir\/2025\/10\/17\/5576\/the-antifungal-landscape-2\/","url_meta":{"origin":5569,"position":3},"title":"The Antifungal Landscape – 2","author":"Harald","date":"October 17, 2025","format":false,"excerpt":"As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1]\u00a0 There is a shortage of new antifungals for invasive disease.\u00a0Small improvements in PK will hardly move the field forward or excite investors to engage.\u00a0Our current\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/HR_SLIDER-The-Antifungal-Landscape-2.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/HR_SLIDER-The-Antifungal-Landscape-2.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/HR_SLIDER-The-Antifungal-Landscape-2.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5392,"url":"https:\/\/allphasepharma.com\/dir\/2025\/09\/22\/5392\/olorofim-in-a-tight-spot\/","url_meta":{"origin":5569,"position":4},"title":"OLOROFIM in a TIGHT SPOT","author":"Harald","date":"September 22, 2025","format":false,"excerpt":"Regulatory and development status of Olorofim, a novel antifungal.","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Picture3-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Picture3-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Picture3-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Picture3-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Picture3-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/09\/Picture3-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2625,"url":"https:\/\/allphasepharma.com\/dir\/2016\/07\/13\/2625\/aspergillus_guideline-zip\/","url_meta":{"origin":5569,"position":5},"title":"Aspergillus_Guideline.ZIP","author":"Harald","date":"July 13, 2016","format":false,"excerpt":"Now, I know we should not make light of any IDSA Guidelines, far from it. This latest, the Aspergillus Guideline [1], like others before, is a thoughtful document which reviews the newest information and reflects expert authoritative thinking on the subject. It also is a hefty 60 pages long, as\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Rules-Regx-Guidelines - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/07\/Rules-Regx-Guidelines-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/07\/Rules-Regx-Guidelines-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/07\/Rules-Regx-Guidelines-slider.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=5569"}],"version-history":[{"count":10,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5569\/revisions"}],"predecessor-version":[{"id":5607,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5569\/revisions\/5607"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/5574"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=5569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=5569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=5569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}